ISCD Learning
PHPT 2023: New Concepts, New Guidelines (On Demand)
-
Register
- Non-Member - $25
- Full Member - Free!
- MOC Only - Free!
- Community Member - $25
- Professional Member - Free!
Activity approved for 1.0 ASRT Category A Credits
Activity approved for up to 1.0 AMA PRA Category 1 Credits™
Activity Expires August 1, 2024
Activity Description
This activity will give an update on diagnosis and indications for surgery with a focus on bone. This activity was designed to allow learners to understand how to approach which patients to refer for surgery for hyperparathyroidism.
Learning Objectives
1. The attendee will understand the current guidelines for when to refer patients with hyperparathyroidism for surgery.
2. The attendee will understand that in patients with eGFR<60, hyperparathyroidism is a more aggressive disease and warrants surgery.
3. The attendee will understand that there is no clear benefit to quality of life parameters associated with parathyroidectomy.
Instructions
Clinicians and Technologists are required to answer a set of online test questions following the review of the video and will have up to three attempts to answer questions correctly before losing credit for the activity. Once the activity test has been passed (75% or higher), you will be asked to evaluate the activity online and then be allowed to claim credit and print certificates.
Registration Fees
Cancellation Policy
On-Demand/ Enduring Material Cancellation Purchases of on-demand or enduring educational materials are non-refundable.
On-Demand/Enduring Material Program Changes or Cancellations ISCD reserves the right to cancel the program and/or change dates of offering. All program fees will be refunded if a program is canceled unless the registered participant elects to transfer to another program.
ACCME Accreditation Statement
The International Society for Clinical Densitometry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to offer continuing medical education for physicians. This activity is provided by the International Society for Clinical Densitometry. For information about the accreditation of this program, please contact ISCD at +1.860.259.1000 or inquire at education@iscd.org.
AMA PRA Category 1 Credit(s)™
The International Society for Clinical Densitometry designates this enduring educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credits commensurate with the extent of their participation in the activity.
ASRT Credit Designation
This activity has been approved by ASRT for 1.00 Category A continuing education credits.
Date of Original Release and most recent Review or Update
This activity was most recently reviewed and released on May 22, 2023, and will expire on August 1, 2024.
John P. Bilezikian, MD, PhD
Professor of Medicine, Vice Chair
Columbia University, Vagelos College of Physicians & Surgeons, Department of Medicine for International Education and Research
Dr. Bilezikian, the Dorothy L. and Daniel H. Silberberg Professor of Medicine at the Vagelos College of Physicians & Surgeons, Columbia University, is Vice Chair of the Department of Medicine for International Education and Research and Chief, Emeritus, of the Division of Endocrinology. He is Director, Emeritus, of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency, and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the National Institutes of Health in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach. He belongs to a number of professional societies including the American Society of Bone and Mineral Research, of which he served as President (ASBMR), 1995-1996 and the International Society of Clinical Densitometry (ISCD), of which he served as President, 1999-2001. He is a member of the Endocrine Society, the American Federation for Clinical Research, the American Society for Clinical Investigation, the Association of American Physicians, the American Association of Clinical Endocrinologists, the American Society for Pharmacology and Experimental Therapeutics, and the American College of Endocrinology that has designated him Master. He served on the Board of Governors of the International Osteoporosis Foundation (1999-2015) and is a current member of its Committee of Scientific Advisors. He is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism and as Senior Associate Editor of the Journal of Bone and Mineral Research. He is Executive Advisory Editor of Bone Research. His books include Editor-in-Chief of The Parathyroids (1994, 2001, 2015), and co-editor of The Aging Skeleton (1999), Dynamics of Bone and Cartilage Metabolism (1999, 2006), Principles of Bone Biology (1996, 2002, 2008, 2020) and Osteoporosis in Men (2010). He is Editor-in-Chief of the 9th and 10th Editions of the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2019, 2023). He has been on numerous panels, including serving as Chair of the NIH Consensus Development Panel on Optimal Calcium Intake (1994), Co-chair of the last four International Workshops on Primary Hyperparathyroidism (2002, 2008, 2013, 2022) and of the International Workshops on Hypoparathyroidism (2015, 2022) and Controversies in Vitamin D (2017-). Dr. Bilezikian's major research interests are related to the clinical investigation of metabolic bone diseases, particularly primary hyperparathyroidism, hypoparathyroidism and osteoporosis, His studies of parathyroid hormone in these disorders regarding etiology, clinical manifestations, pathophysiology, mechanisms of skeletal involvement, and therapy are known throughout the world as landmark contributions to our knowledge of these disorders. He has been continuously funded by the NIH since 1974. Over 925 publications speak to these active original investigative initiatives as well as his authorship of many reference sources of endocrinology and metabolic bone diseases.
Dr. Bilezikian is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the ASBMR for Excellence in Clinical Research, and the First Annual Global Leadership Award of the ISCD. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of the Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism and the Association of Brazilian Orthopedic Osteologists. In 2015, he received the Oscar Gluck Humanitarian Award of the ISCD and the Inaugural Global Educator of the Year Award from McMaster University in Canada. In 2017, he was named Honorary Member of the Russian Osteoporosis Association. Dr. Bilezikian has received Lifetime Achievement and Recognition Awards of the California and Boston Armenian American Medical Societies and the Armenian American Health Professionals Organization. In 2017, he received the Doctor Honoris Causa Award from the Carol Davila School of Medicine in Bucharest, Romania and from the University of Pisa, in Pisa, Italy. He received the Distinguished Physician Award of the American Association of Clinical Endocrinologists in 2018. He received the Ellis Island Congressional Medal of Honor from the United States Government in 2018. Also, in 2018 he received a Parliamentary Medal of Honor from the Government of Armenia for distinguished service and a similar honor from the Government of Brazil. In 2019, he received the Gold Medal for Outstanding Achievements in Medical Research, the highest honor that Columbia University’s College of Physicians and Surgeons bestows on its graduates. In 2020, Dr. Bilezikian received the ASBMR William F. Neuman Award for highest scientific achievement. In 2023, he received a Special Recognition Award from the 6th International Medical Congress of Armenia.
Course Planners and Managers
Harold Rosen, MD, CCD No Financial Relationships to Disclose
Jill Seely, BS, CMA, CAHI No Financial Relationships to Disclose
Fiore Barbini No Financial Relationships to Disclose
Course Content Reviewers
Wendy Tolman-Andrews, CBDT No Financial Relationships to Disclose
Course Faculty, Moderators, and Content Authors
John Bilezikian, MD, PhD - Disclosures: Amgen, Abiogen, Ascendis, NovoNordisk, Takeda Pharmaceuticals, Radius, Ultragenyx: Advisory Boards and Consultant Fees; Regeneron; Data and Safety Monitoring Board
Statement of Independence
The ISCD maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the ISCD provide in-depth presentations that are fair, balanced, independent, and scientifically rigorous. ISCD requires faculty, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ISCD for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Individual disclosures are included in the course material. No Commercial Support has been provided for this activity
Disclaimer
The information and suggestions presented at the courses, seminars and other programs sponsored by ISCD and other collaborating societies are subject to change and therefore should serve only as a foundation for further investigation and study. Any forms presented at our seminars or programs are samples only and are not necessarily authoritative. All information, procedures, and forms contained or used in such seminars or programs should serve only as a guide for use in specific situations.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. ISCD does not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Privacy & Confidentiality Statement
The ISCD will record the learner’s personal information as provided on evaluations to allow for the issuance and tracking of CME/CE certificates. The ISCD may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its educational program. No individual performance data or any other personal information collected for evaluations will be shared with third parties
Attendee Cancellation Policy
All changes in registration must be made in writing to education@iscd.org. Purchase of on-demand or enduring educational materials are non-refundable.
Course Changes or Cancellations
ISCD reserves the right to cancel the program and/or change dates of offering. All program fees will be refunded if a program is canceled unless the registered participant elects to transfer to another program.
Key:
Complete
Next
Failed
Available
Locked